A Retrospective, Multicenter Study of the Tolerance of Induction Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Radiotherapy With Concomitant Cetuximab in 46 Cases of Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 430-437

  Buiret, Guillaume ^a,b   Combe, Claire ^b   Favrel, Véronique ^a   Pommier, Pascal ^c   Martin, Laurent ^d   Ecochard, René ^b   Fayette, Jérome ^c   Tartas, Sophie ^e   Ramade, Antoine ^e   Céruse, Philippe ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Clinique des Ormeaux   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Adjuvant chemotherapy; Head and neck neoplasms; Radiation tolerance; Radiotherapy; Safety

Indexed keywords

ACCIDENT PREVENTION; RADIOTHERAPY;

ADJUVANT CHEMOTHERAPY; ANTIBIOTIC TREATMENT; EXTERNAL RADIOTHERAPY; FUTURE IMPROVEMENTS; HEAD AND NECK NEOPLASMS; INDUCTION CHEMOTHERAPY; RADIATION TOLERANCES; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKS;

CHEMOTHERAPY;

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ACNE; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY SPASM; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HOSPITALIZATION; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; LUNG DISEASE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DERMATITIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 77951945747     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.066     Document Type: Article

References (38)

1. Jacobs J., Pajak T., Kinzie J., et al. Induction chemotherapy in advanced head and neck cancer: A Radiation Therapy Oncology Group study. Arch Otolaryngol Head Neck Surg 113 (1987) 193-197
2. Ensley J.F., Jacobs J.R., Weaver A., et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54 (1984) 811-814
3. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
4. Pignon J.P., le Maitre A., Bourhis J., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update. Int J Radiat Oncol Biophys 69 Suppl. 2 (2007) S112-S114
5. Vermorken J.B., Remenar E., Van Herpen C., et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). (Abstr.). J Clin Oncol 22 Suppl. (2004) 14
6. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 8636-8645
7. Calais G., Pointreau Y., Alfonsi M., et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. (Abstr.). J Clin Oncol 24 Suppl. (2006) 18s
8. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
9. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
10. Hitt R., Grau J., Lopez-Pousa A., et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). (Abstr.). J Clin Oncol 24 Suppl. (2006) 18
11. Specenier P., and Vermorken J.B. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 19 (2007) 195-201
12. Chan T.O., Rittenhouse S.E., and Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68 (1999) 965-1014
13. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (1997) 1523-1530
14. Engebraaten O., Bjerkvig R., Pedersen P., et al. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 53 (1993) 209-214
15. Rubin Grandis J., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
16. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
17. Harari P.M., and Huang S.M. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49 (2001) 427-433
18. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
19. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol 24 (1997) 602-615
20. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008) 1116-1127
21. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
22. Bourhis J., Rivera F., Mesia R., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006) 2866-2872
23. Humblet Y., Vega-Villegas E., Mesia R., et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). (Abstr.). J Clin Oncol 22 Suppl (2004) 14
24. Vermorken J., Bourhis J., Trigo J., et al. Cetuximab (Erbitux®) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. (Abstr.). J Clin Oncol 23 Suppl. (2005) 16s
25. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
26. Trigo J., Hitt R., Koralewski P., et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. (Abstr.). J Clin Oncol 22 Suppl. (2004) 14s
27. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
28. Kies M.S., Garden A.S., Holsinger C., et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). (Abstr.). J Clin Oncol 24 Suppl. (2006) 18
29. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078
30. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
31. Wittekind C., Greene F., Hutter R., et al. TMN Atlas: Guide illustre de la classification TMN/pTMN des tumeurs malignes. 5th ed (2006), Springer, Paris
32. Pinheiro J., and Bates D.M. Mixed effects models in S and S-plus. Statistics and computing series (2000), Springer-Verlag, New York
33. Hanna E., Alexiou M., Morgan J., et al. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: Efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 130 (2004) 861-867
34. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
35. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
36. Adelstein D.J., Saxton J.P., Lavertu P., et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head Neck 19 (1997) 567-575
37. Machtay M., Moughan J., Trotti A., et al. Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: An RTOG analysis. J Clin Oncol 24 Suppl. (2006) 18
38. Calais G., Bardet E., Sire C., et al. Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys 58 (2004) 161-166